Articles > insulin

Everything you need to know this week about type 1 diabetes and coronavirus updates, in one easy-to-read place!

Lately, we are inundated with negative reports and information surrounding the Coronavirus outbreak. Fortunately, there is some good news for people with type 1 diabetes. Eli Lilly announced that beginning April 6, 2020, and for $35.00 dollars a month regardless of having a health insurance plan or not having health insurance at all, people with …

As the novel coronavirus COVID-19 continues to spread in the United States, many people are understandably concerned about access to their medications. Health officials and medical professionals working in federal, state and local governments recommend that high-risk individuals with underlying health conditions such as Type 1 Diabetes, stock up on their prescription medications, in addition to practicing basic hygiene and avoiding crowded places.

the liver can be just as important as the pancreas in treating type 1 diabetes

Diasome Pharmaceuticals announced positive results this week from a Phase 2 study of its injectable hepatocyte directed vesicle (HDV) additive for insulin in patients with type 1 diabetes. The news could prove a major step forward for therapies that aim to improve and optimize the way insulin is used and metabolized by the body. In …

Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.

Fiasp fast acting insulin pen

The U.S. Food and Drug Administration has approved Novo Nordisk's fast-acting Fiasp insulin for use in children as well as adults, the pharmaceutical firm announced Monday.

A patient loads insulin for his routine shot.

At least 17 states have passed laws carving out exceptions for pharmacists to fill insulin prescriptions during emergency situations. These legal reforms are seen by some advocates as the first real sign of progress for improved access to insulin in the United States.

logo for French pharma manufacturer Sanofi

Sanofi, the French pharmaceutical giant which manufactures the long-acting insulin Lantus, announced Monday that it would no longer be investing in research for new drugs to treat diabetes. The manufacturer also told investors it would no longer be investigating new treatments for cardiovascular health. “To be out of cardiovascular and diabetes is not easy for …

Insulin Singled Out in Ambitious Bill By House Democrats to Lower Drug Prices

The bill would mandate that the government negotiate with drug makers about the price of insulin, both in the Medicare program and for the open insurance market. It also includes many other mechanisms intended to lower the price of insulin and other drugs.

ere are Six Recent Moves to Curb Co-Pay Costs for Insulin

Four insurers have introduced a cap on monthly insulin costs, but the federal government’s move to change regulations around high-deductible insurance plans may have the biggest long-term impact.